A meta-analysis of 6 RCTs with 4,325 patients found oral atogepant significantly reduced monthly migraine days (SMD -0.39, p<0.00001, I²=0%) with a favorable safety profile for migraine prophylaxis.
Zero heterogeneity (I²=0%)Atogepant's migraine day reduction was remarkably consistent across all 6 trials, indicating a robust and reliable treatment effect
What the researchers found
Atogepant significantly reduced MMDs vs placebo (SMD -0.39, 95% CI -0.45 to -0.33; p<0.00001; I²=0%). Also significantly reduced MHDs, monthly acute medication use days, and increased ≥50% MMD responder rates. Safety profile was acceptable.
Why it matters
Atogepant offers an oral CGRP-targeting option for patients who prefer pills over injections for migraine prevention. The zero heterogeneity confirms a remarkably consistent effect across diverse trial populations.
How the study worked
PRISMA-compliant meta-analysis of 6 RCTs (3,054 atogepant, 1,271 placebo). Cochrane CENTRAL, PubMed/MEDLINE, Google Scholar through July 2024. Inverse variance and Mantel-Haenszel random-effects models.
What this study cannot tell us
Limited long-term data. Head-to-head comparisons with other CGRP drugs are lacking. Cost-effectiveness not assessed.
How to read the evidence
Meta-analysis of 6 RCTs—high-quality evidence with excellent consistency (I²=0%).
When this study was published
Published in 2025; literature through July 2024.
The bigger picture
Oral CGRP antagonists like atogepant are democratizing access to CGRP-targeted migraine prevention, previously available only as injectable antibodies. This provides more options for the 15% of the global population affected by migraine.
Questions still open
- How does atogepant compare to injectable CGRP antibodies in long-term efficacy?
- Is atogepant cost-effective compared to other migraine preventives?
- Which patients respond best to oral CGRP antagonists vs antibodies?
Common questions
What is atogepant?
How well does atogepant work?
Read the original research
"The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials".
BMC neurology, 25(1), 326
Citation
Shaukat, Ayesha; Shakeel, Laiba; Riaz, Rumaisa; Ashraf, Saad; Akilimali, Aymar. (2025). "The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials".. BMC neurology, 25(1), 326. https://doi.org/10.1186/s12883-025-04350-x